Introduction {#sec1-1}
============

Salivary gland tumors (SGTs) are among the relatively rare group of neoplasms characterized by the wide range of biological behaviors and a variety of benign and malignant types. The annual incidence of SGTs is approximately 0.4 to 13.5 cases per 100,000 individuals, about 3-6% of all head and neck cancers\[[@ref1]-[@ref4]\]. SGTs are considered to have multifactorial etiology, and histopathologic characteristic complicates their diagnosis and management. The management requires distinctive surgical and adjuvant therapy, but the early detection plays an important role in successful therapy and reduces the severity of its impact on the patient\'s life\[[@ref3]-[@ref4]\]. Despite a low prevalence, a number of factors such as the complex histopathological diagnosis, grade of malignancies, varied clinical behaviors and risk of recurrence pose the major challenges for the pathologists and clinicians to achieve the effective treatment\[[@ref3]-[@ref5]\].

Paxillin is a 68-kDa focal adhesion-associated adaptor protein, which is originally identified as a tyrosine phosphorylated protein in chick embryo fibroblasts. Paxillin is localized at the intracellular surfaces where the cells adhere to the extracellular matrix. The function has not been well characterized, but it has been proposed that paxillin acts as an oncogene in many malignancies and involved in key signal transduction, cell motility, migration, proliferation, survival, angiogenesis, and apoptosis\[[@ref6]-[@ref10]\]. A number of studies have been evaluated the expression of paxillin and shows the deregulation and its role in the development of various human carcinomas such as the squamous cell carcinoma\[[@ref11]\], esophageal squamous cell carcinoma\[[@ref12]\], lung\[[@ref13]-[@ref14]\], breast\[[@ref15]\], cervical\[[@ref16]\], colorectal\[[@ref9]\], and prostate cancers\[[@ref17]-[@ref18]\]. Furthermore, it was shown that paxillin level significantly associated with the progression and metastasis of malignancies. Patients with high paxillin expression had poorer prognosis and survival rate compared to those with low paxillin expression. However, the underlying mechanisms of paxillin overexpression remain unresolved. Therefore, paxillin might be a potential therapeutic target to suppress tumor progression\[[@ref6],[@ref9],[@ref19]-[@ref21]\]. To the best of our knowledge and among the different type of SGTs, only one study has evaluated the expression of paxillin in patients with salivary adenoid cystic carcinoma (ACC)\[[@ref22]\]. However, the role and its expression in the other types of SGTs still need to be clearly elucidated. Therefore, the current study aimed to determine the expression levels of paxillin and its prognostic and clinicopathological significance in Iranian patients with benign and malignant SGTs.

Materials and Method {#sec1-2}
====================

Study Population {#sec2-1}
----------------

A total of 50 paraffin-embedded SGTs tissues from patients who underwent surgery in the ENT department of Khalili Hospital and School of Dentistry both affiliated to Shiraz University of Medical Sciences, were enrolled in this retrospective study. All the patients had a histologically confirmed diagnosis of SGTs and received no treatment prior to surgery. The patient group consisted of 19 (38%) male and 31 (62%) females whose age ranged from 19 to 81 years (mean age of 47.6±17.3). Patients were divided into 2 groups of benign (n = 17) and malignant (n = 33). All of the benign tumors were pleomorphic adenoma (PA) while the malignant cases were as follows: 16 patients with mucoepidermoid carcinoma (MEC) and 17 patients with ACC.

On the other hand, 19 specimens including 8 male (42.1%) and 11 female (57.9%) with the mean age of 56.5±16.1 years (range 38-81 years) were also kept from those with normal salivary gland (NSG) adjacent to the tumoral tissues as a control group of this study. Relevant clinicopathological characteristics such as age, gender, tumor size, lymph node, and distant metastasis were obtained from the patients' medical database. The common tumor-node-metastasis (TNM) staging system was used for classification of all histologic variants of SGTs based on the American Joint Committee on Cancer (AJCC). The research protocol was approved by the Ethics Committee of Shiraz University of Medical Sciences, and all participants gave written informed consent for using their samples for research purpose.

Immunohistochemistry {#sec2-2}
--------------------

Immunohistochemical staining was used to detect paxillin expression with standard protocols. Briefly, formalin-fixed paraffin-embedded tissue blocks were cut serially into 4μm. Sections were deparaffinized with xylene, rehydrated through a graded alcohol series, and treated with 3% hydrogen peroxide in methanol to block endogenous peroxidase activity. Then, the sections were rinsed with phosphate-buffered saline and subjected to microwave antigen retrieval in 0.01 mol/L sodium citrate buffer (pH 6.0). An anti-paxillin antibody (Rabbit, Abcam Corporation, ab 32084, USA) was used as the primary antibody, followed by the streptavidin-horseradish peroxidase complex. Finally, binding was visualized with 3, 3 diaminobenzidine (DAB) chromogen and all the sections were counterstained with hematoxylin. HeLa cells (line from cervical cancer cells) were used as positive control and negative control was obtained by omission of the primary antibody.

To quantify the paxillin expression, both the percentage and intensity of immunoreactivity were assessed and scored. The percentage of staining was graded according to the percentage of cells that had positive immunoreactivity in every microscopic field: 0= less than 25%; 1=weak (25‑50%); 2= moderate (\>50‑75%); and 3= strong (\>75-100%). The staining intensity score ranging from 0 to 3 and graded as follows: 1= weak; 2= moderate; and 3= strong. By multiplying the scores for percentage and intensity, a total score was achieved (ranged from 0 to 9). According to the immunohistochemical results of paxillin staining, patients were divided into two groups of paxillin low-level expression and paxillin high-level expression. The score of 4 and more than 4 was rated as "high" paxillin expression whereas a score less than 4 was rated as "low" paxillin expression\[[@ref8]\].

Statistical analysis {#sec2-3}
--------------------

The statistical analysis was performed using the SPSS software package (version 21, SPSS Inc, Chicago, USA). The comparison of paxillin expression and association between clinicopathological characteristics and paxillin expression was analyzed by the chi-square and ANOVA test. A *p* value of less than 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Paxillin was mainly localized in the cytoplasm of tumor cells and all samples (100%) included in this study was expressed paxillin ([Table 1](#T1){ref-type="table"}).

###### 

Paxillin overexpression in benign and malignant salivary gland tumors in comparison with normal salivary gland tissues

  Types of lesion   Number of patients   High Paxillin expression, N(%)   Low Paxillin expression N(%)
  ----------------- -------------------- -------------------------------- ------------------------------
  ACC               17                   12(70.6)                         5(29.4)
  MEC               16                   9(56.3)                          7(43.8)
  PA                17                   12 (70.6)                        5(29.4)
  Normal            19                   0 (0)                            19 (100)

Paxillin expression was mainly seen in ductal cells of NSG. In PA and ACC both ductal and myoepithelial cells showed paxillin positivity ([Figures 1](#JDS-20-249-g001.tif){ref-type="fig"} to [](#JDS-20-249-g002.tif){ref-type="fig"}[](#JDS-20-249-g003.tif){ref-type="fig"}[4](#JDS-20-249-g004.tif){ref-type="fig"}).

![Cytoplasmic paxillin expression in normal salivary gland (200×)](JDS-20-249-g001){#JDS-20-249-g001.tif}

![Cytoplasmic paxillin expression in pleomorphic adenoma (200×)](JDS-20-249-g002){#JDS-20-249-g002.tif}

![Cytoplasmic paxillin in mucoepidermoid carcinoma (200×)](JDS-20-249-g003){#JDS-20-249-g003.tif}

![Cytoplasmic paxillin in adenoid cystic carcinoma (200×)](JDS-20-249-g004){#JDS-20-249-g004.tif}

The expression of paxillin is higher in the SGTs than that in the NSG {#sec3-1}
---------------------------------------------------------------------

Among the study groups, the percentage and intensity of paxillin expression were strong in 58% of SGTs cases (29 of 50). Most of the patients with NSG showed weak paxillin positivity (94.7%) and moderate paxillin intensity (68.4%) while the strong intensity diagnosed in only 2 (10.5%) cases. The paxillin total score was signi-ficantly higher in SGTs than NSG (Table 1) (*p*\< 0.0001).

The relationship between paxillin expression and clinicopathological characteristics {#sec3-2}
------------------------------------------------------------------------------------

Next, we analyzed the paxillin expression levels in patients with benign and malignant tumors and found no significant difference (*p*= 0.930). The expression levels of paxillin appeared to be similar among the 3 subgroups (PA, MEC and ACC) of SGTs (*p*\> 0.05), but there was a significant difference between PA, MEC and ACC groups with that of the NSG (*p*\< 0.0001) ([Table 1](#T1){ref-type="table"}). Our results indicated that 70.6%, 56.3% and 70.6% of patients with PA, MEC, and ACC rated as high paxillin expression, respectively. Immunohistochemistry analysis revealed that there were no differences between genders, age, tumor size, lymph node metastasis, and TNM stage regarding paxillin expression ([Table 2](#T2){ref-type="table"}) (*p*\> 0.05).

###### 

Clinicopathologic characteristics of the 33 patients with malignant salivary gland tumors

  Variable   N (%)      Paxillin protein (High expression) N(%)   Paxillin protein (Low expression) N(%)   *p* value
  ---------- ---------- ----------------------------------------- ---------------------------------------- -----------
  T Status                                                                                                 
  T1+T2      25(75.7)   15(60)                                    10(40)                                   0.8
  T3+T4      8(24.3)    6(75)                                     2(25)                                    
  N Status                                                                                                 
  N0         24(72.7)   16(66.6)                                  8(33.4)                                  0.2
  N1         9(27.3)    5(55.5)                                   4(44.5)                                  
  M Status                                                                                                 
  M0         30(90.9)   18(60)                                    12(40)                                   0.4
  M1         3(9.1)     3(100)                                    0(0)                                     
  Stage                                                                                                    
  I+II       22(66.6)   15(68.1)                                  7(31.9)                                  0.2
  III+IV     11(33.4)   6(54.5)                                   5(45.5)                                  

Discussion {#sec1-4}
==========

Paxillin serves as an important multifunctional protein with scaffolding role that provides the binding sites between the plasma membrane and the actin cytoskeleton. This platform is necessary for the integration and processing of adhesion and growth factor-related signals that are mainly involved in tumor migration, invasion, and metastasis\[[@ref20],[@ref23]-[@ref24]\]. Recent studies have reported that paxillin expression differs among various malignancies and promotes the tumor progression\[[@ref22],[@ref25]-[@ref26]\]. However, despite the extensive investigations of paxillin expression, little information is available in SGTs. The incidence of SGTs in Iranian population estimated to be 0.4- 4.9%\[[@ref27]-[@ref29]\]. Therefore, due to the prevalence and importance of SGTs, the current study was intended to evaluate the expression of paxillin in tissue samples of Iranian patients with benign and malignant SGTs.

Our study evaluated the expression of paxillin by the use of both the percentage and intensity of paxillin immunoreactivity. Paxillin was expressed in all of the tissue samples, but the SGTs showed the higher expression of paxillin in all three subgroups (PA, MEC, and ACC) compared with that of NSG, which suggested the crucial role of paxillin in tumorgenesis. We found high paxillin expression in patients with PA, MEC, and ACC (70.6%, 56.3% and 70.6%), respectively. To our knowledge, only one report has explored the expression of paxillin in patients with SGTs. Shi *et al*.\[[@ref22]\] evaluated the 47 cases of salivary ACC and showed paxillin expression in 57.45% of patients which is lower than that of observed in our series. The difference between these two studies maybe related to different immunohistochemistry evaluation and sample size.

Paxillin was highly expressed in 66% of our patients, which is similar to the results of patients with hepatocellular carcinoma\[[@ref26]\], but differs from urothelial bladder tumor\[[@ref30]\]. On the other hand, all the patients with NSG rated as low paxillin expression. In accordance to our results, almost all previous studies such as those conducted on patients with laryngeal squamous cell carcinoma\[[@ref20]\], esophageal squamous cell carcinoma\[[@ref12]\], colorectal cancer\[[@ref8]\], lung cancer\[[@ref13]\], gastric cancer\[[@ref6]\], and colorectal cancer\[[@ref9]\] show the higher expression of paxillin in cancerous tissues compared with that of observed in their controls. Furthermore, paxillin could not differentiate between benign and malignant cases. Our results revealed that paxillin expression was not correlated with clinicopathological parameters of patients with SGTs. It is in contrast with the results of Shi *et al*.\[[@ref22]\] in which paxillin expression was associated with clinical stage and distant metastasis, but not with histologic type. Similar results were obtained in patients with colorectal cancer\[[@ref19],[@ref31]\], and hepatocellular carcinoma\[[@ref26]\].

High expression of paxillin was significantly correlated with the advanced TNM stage in gastric cancer\[[@ref6]\], prostate cancer\[[@ref32]\], colorectal cancer\[[@ref19]\], laryngeal squamous cell carcinoma\[[@ref20]\], and salivary ACC\[[@ref22]\]. However, the relationship between paxillin expression and advanced clinical stages was not reached in this study, because of small sample size of malignant tumors. So due to the relatively small number of samples, further investigation of its potential is highly warranted, especially when early detection of patients could improve the prognosis and survival rate.

In summary, the present study showed that paxillin expression of SGTs was significantly higher than NSG, which highlight the important role of paxillin expression in the development of tumors. However, it is not correlated with clinicopathologic factors of patients. Our study had some limitations. First, this is a retrospective study and not well controlled. In addition, this study concerned the small number of patients and relatively few clinical events, limiting our ability for precise conclusions. Further studies with larger sample size will be required to assess the potential roles of paxillin for the early detection of SGTs.

Conclusion {#sec1-5}
==========

High expression of paxillin was observed in tumoral tissues compared with the controls that establish an important role of paxillin in SGTs but its prognostic role was unclear and need further evaluation.
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